From Stocktwits: 2025-02-24 23:02:15

Retail traders on Stocktwits are buzzing about Summit Therapeutics, Inc.’s partnership with Pfizer to evaluate ivonescimab for solid tumors, leading to a 2,500% increase in message volume. Despite a selloff after disappointing Q4 earnings, sentiment rebounded in after-hours trading due to the collaboration. Summit reported a Q4 net loss of $61.1 million and adjusted operating expenses of $54.8 million. The collaboration with Pfizer will involve clinical trials starting in mid-2025, with both companies retaining full rights to their respective drugs. Summit stock has surged over 330% in the past year and is up 4% year-to-date.



Read more at Stocktwits: Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown